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the treatment of asthma were not accepted due to comments about population 
and model input, lack of statistical calculations and size of the incremental effects. 
Ranibizumab’s results for age-related macular degeneration were not accepted 
because of a wrong comparator, lack of long term data, assumptions on risks and 
mortality, and uncertainties around health care costs and ICER sensitivity. Finally, 
ZiNL considered the appropriate use of alglucosidase alfa for Pompe’s disease 
to be unsubstantiated because of the population choice for the ICER calculation 
and the use of a higher dose than the registered dose which was not supported 
by scientific data. The outcome results of alglucosidase alfa for cost-effectiveness 
were accepted, however. ConClusions: Although at T= 0 ZiNL provided feedback 
regarding the design of the outcome research study, most of ZiNL’s comments were 
on the final methodology used. The outcome research studies were considered 
to be of mixed quality and the results could often not substantiate the claim of 
cost-effectiveness and appropriate use.
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objeCtives: In the UK, when a technology is recommended by the National 
Institute for Health and Care Excellence (NICE), the NHS is mandated to provide 
the funding to accommodate it within three months. Explicit in NICE’s approach 
to health technology assessment (HTA) is the assumption that the approval of a 
new, cost-increasing technology will result in the displacement of an existing, less 
cost-effective health care programme from elsewhere in the NHS. The objective 
of this study is to identify the actual opportunity costs of specific NICE decisions 
by documenting how in practice local commissioners in Wales accommodated 
financial shocks arising from technology appraisals (TAs). Methods: Interviews 
were conducted with Finance and Medical Directors from all seven Local Health 
Boards (LHBs) in NHS Wales. These interviews covered prioritisation processes, as 
well as methods of financing NICE TAs and other financial “shocks” at each LHB. 
We then undertook a systematic identification of themes and topics from the 
information recorded. Results: The financial impact of NICE TAs is generally 
planned for in advance and the majority of LHBs have contingency funds avail-
able for this purpose. Efficiency savings (defined as reductions in costs with no 
assumed reductions in quality) were a major source of funds for all cost pressures. 
Service displacements were not linkable to particular TAs and there appears to be 
a general lack of explicit prioritisation activities. The Welsh Government has, on 
occasion, acted as the funder of last resort. ConClusions: The assumption that 
newly recommended technologies will displace existing NHS services does not 
appear to hold true in practice. As the additional cost pressures represented by 
new NICE TAs are likely to be accommodated by greater efficiency and increased 
expenditure, the true opportunity cost of HTA decisions is extremely difficult to 
quantify and may even lie outside the NHS.
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objeCtives: Western countries health care systems face growing challenges deal-
ing with disability and death due to chronic diseases. Coordination of health care 
services has become unavoidable. Our objective was to identify the Integrated 
Health Services (IHS) in the major health care markets and understand the fund-
ing process. Methods: IHS provided in Europe, North America and Asia were 
identified through a literature review. Future perspectives were based on country 
policy and observed trends. Results: All studied countries developed IHS such 
as disease management, case management and telemonitoring services, with the 
United States (US) being the major market. However, levels of implementation, 
funding processes and stakeholders involved vary highly between different coun-
tries. Funding processes such as fee for services and capitation are widely used in 
all studied countries and Payment for performance (P4P), bundled payment and 
diagnosis-related group (DRG) for outpatient are in progress, used mainly in the 
US, and to a much lower extent in the United Kingdom (UK) and Germany. Multiple 
IHS exists in France, though inappropriate incentives hinder their development. In 
the US, under the Affordable Care Act, Accountable Care Organisations (ACOs) are 
testing a range of payment models (capitation, one-sided/two-sided shared sav-
ing fee-for-service, bundled/episode payments and P4P). ConClusions: IHS have 
become ubiquitous in all health organisations. All countries studied are expected to 
develop more IHS based on P4P schemes. The P4P of ACOs represents the ultimate 
gold mine for the development of paid health care services. Even if this concept is 
still in progress it will be leading this market. This will also change dramatically the 
way pharmaceutical companies will do business. Drugs will have to be integrated 
in a more complex selling process driven by medium to long term outcome impact. 
The management of confounding factors on outcomes is critical and represents 
the challenge for ACOs.
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objeCtives: The comprehensive implementation of telemedical applications still 
lags behind expectations in Germany. One of the main barriers to innovation is a 
lack of both a willingness to adapt and user’s acceptance. Processes of adoption 
and acceptance are characterized by a network of different factors which influ-
ence attitude and behavior which differ in severity depending on each user group. 
One key factor for accepting and adopting an innovation is the economic frame-
work. We therefore examined the influence of economic factors influencing the 
Senegal, Egypt, Morocco, Algeria and Tunisia) are contributing # 80% of the pharma 
market in Africa. Despite maintaining regional offices within Africa, many major 
Pharma and device manufacturers frequently overlook the continent when sponsor-
ing clinical studies. Cultural barriers, political upheaval and uneven infrastructure 
are certainly causes for the lack of interest. But Africa offers tremendous expertise 
and opportunity for drug and device companies looking for cost-effective study 
sites and appropriate patient drug market populations. Currently more than 45% 
of the whole continent’s clinical trials are being conducted in South Africa and 
hence the need for the next generation clinical trial destination for a drug and 
device manufacturers. These companies can also consider technology transfer by 
partnering with local drug manufacturers and research centers to diversify their 
business portfolio. ConClusions: Africa presents real opportunities that should 
encourage many pharmaceutical companies to really engage in innovative clinical 
research programs in a win-win approach.
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objeCtives: Although, whether biologically active supplements (BAS) are medi-
cines or not is still debatable, BAS keep making their way to the customer basically 
through pharmacies. A worldwide tendency toward “greener” choices when pur-
chasing health status modifiers (HSM) is well documented. Current endeavor studies 
the pharmaceutical market situation (PMS) in Armenia (2009 to 2013) in regard to 
growth trends both in US dollars turnover (USDT) and number of packs sold (NPS) of 
BAS versus medicines, stratified by five leading diseases (LD). Methods: Statistical 
data on morbidity and mortality from the MOH RA were used to identify the leading 
five disease groups in newly identified cases. Further, statistical data on pharmaceu-
tical market from “Pharmexpert” Marketing Research Centre (analysis of wholesale 
sales volumes to the retail drug stores) were investigated to identify growth rate 
(GR) trends of interest. Results: A PMS analysis has shown 11.92% and 6.65% of 
GR (medicines and BAS combined) in USDT and NPS respectively. For medicines 
alone the results were: 11.56% and 6.23% GR in USDT and NPS respectively. As for 
BAS, USDT and NPS, the figures were 21.48% and 15.36% of GR respectively. A further 
stratification by five LM has shown the highest GR in medicines used for treatment 
of Uro-Genital diseases (13.24% and 10.01% for USDT and NPS respectively), whereas 
in BAS the highest GR was in the Cardio-Vascular group (63.84% and 92.82% for USDT 
and NPS respectively). ConClusions: The results of the study go in line with the 
worldwide trends in shifting whenever possible, from medicines to using HSM of 
natural origin, of which BAS are a major part. The study does not claim to identify 
the underlying compound factors influencing such a tendency. However, the reality 
at had compels for studying the levels of BAS administration and use literacy among 
both HSM prescribers and consumers.
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objeCtives: This study seeks to evaluate the incremental benefit scores granted 
to new medicines under the 2011 AMNOG reform in Germany, and if there is a 
correlation between that score and the extent of price reduction after negotiation 
with the statutory health insurance fund. Methods: Resolutions issued by the 
G-BA related to all drugs which achieved the early benefit assessment process 
between January 2011 and June 2014 were reviewed to determine whether the 
drugs were deemed to bring an added benefit. Under AMNOG, an added therapeu-
tic benefit score is granted to medicines according to 6 categories (major, consid-
erable, minor, non-quantifiable, no or less added benefit versus the comparator). 
As part of the study, IHS created an overall quantitative innovation score for each 
product, based on any and all qualitative ratings granted by the G-BA in each 
patient subgroup. The score ranged from 0 (no added benefit proven) to 4 (major 
added benefit) and was weighted against each patient population. An average price 
reduction per innovation score range was then calculated. Results: Out of the 76 
drugs assessed in the study, a total of 44 were deemed to bring an added benefit 
over the appropriate comparator by the G-BA, of which 34 had achieved price nego-
tiation as of end of May 2014. These ratings translated into an average innovation 
score of 1.77, and were subject to price cuts averaging 21.7%. ConClusions: Our 
analysis highlights that innovative medicines can be subject to significant price 
cuts in Germany. No correlation between the innovation score and subsequent 
price cuts could be derived, as many other factors, including the initial price dif-
ference between the new medicine and the comparator, enter into account as 
part of the price negotiations.
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objeCtives: If the cost-effectiveness and appropriate use of a drug in the 
Netherlands cannot yet be determined during the initial reimbursement assess-
ment (T= 0), this will be done at the re-evaluation 4 years later (T= 4) using RWD. 
Outcome research is an essential part of the re-evaluation of conditionally reim-
bursed drugs. The objective was to assess the reasons for accepting or rejecting 
outcome research results to confirm cost-effectiveness and appropriate use of 
a drug at T= 4. Methods: The website of Zorginstituut Nederland (ZiNL) was 
searched for re-evaluations of drugs published between January 2006 and May 
2014. ZiNL’s assessments of the outcome research were compared. Results: ZiNL 
published the outcome research results for four drugs. The outcome research 
results for agalsidase alfa & beta were accepted for demonstrating cost-effective-
ness and appropriate use in Fabry’s disease. The T= 4 results for omalizumab for 
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attitudes of physicians in Germany towards telemonitoring. Methods: In the first 
step fundamental determinants of adoption and acceptance were identified using 
a systematic literature review and transferred to a theoretical effect model. This 
model was used to create a quantitative questionnaire which was then used to 
interview online 201 outpatient and inpatient physicians from different fields of 
medicine. The participants (84.3% male, mean age 53 years) were asked to assess the 
empirically based economic attributes of telemonitoring regarding its implementa-
tion. Results: The results show a lack of information regarding the financial risks 
of using telemedical technology, as only 14% of those interviewed said they felt 
sufficiently informed about the subject. Barriers to using telemedicine technology 
include missing arrangements for reimbursement, uncertain financial advantages 
and missing business models. In addition, the cost of implementation are indistinct 
for a broad majority of interviewees. On the other hand, in most queried dimension 
the user see a potential financial benefit due to telemedicine. The positive effects 
expected from telemonitoring were rated much better rated by those who already 
used telemonitoring in their professional life. ConClusions: In addition to a more 
precise legal framework, information security and quality-based guidelines, more 
emphasis must be placed on economic issues. It is also imperative that physicians 
be better informed about all aspects of telemedicine.
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objeCtives: In Germany, the AMNOG law replaced free pricing by the early ben-
efit assessment (EBA) since 2011. Manufacturers are free to set new drugs’ prices 
for up to one year after which the price is negotiated between manufacturers 
and insurers based on the EBA. The negotiated price, that is consistently lower 
than the one set by the manufacturers, is considered as the official list price since 
April 1st2014. The objective of this study is to evaluate the potential impact of this 
new law on the external reference pricing (ERP) in Europe. Methods: A simula-
tion model, developed for the European Commission, was used to simulate ERP’s 
impact on Boceprevir and Telaprevir prices after five years, following the discount’s 
inclusion on the official list price in Germany. ERP impact on price was evaluated 
in Belgium, Czech Republic, France, Germany, Luxembourg, Norway, Slovakia, 
Slovenia, Sweden, Switzerland, The Netherlands and UK for Boceprevir and in 
Belgium, Finland, France, Germany, Luxembourg, Norway, Poland, Slovakia, Slovenia, 
Sweden, Switzerland, The Netherlands and UK for Telaprevir. National policy inputs 
were obtained from a literature review and consultation of international organisa-
tions’ representatives. Prices used at the start of the simulation were obtained from 
IMS. Results: After five years, the relative price variation of Boceprevir between 
the scenario with AMNOG discount integrated in the list price and with no dis-
count integrated in the list price was null in Belgium, Luxembourg, Sweden and 
UK, of -8.1% in the Netherlands, -9.2% in Norway, nearly -10% in Czech Republic, 
France, Slovakia and Switzerland, and -14% in Slovenia. For Telaprevir, the price 
variation was null in Belgium, Finland, Luxembourg, Slovenia and the UK, of -0.8% 
in Slovakia, -2.5% in the Netherlands, -2.9% in Norway, -6.9% in France and -8.6% in 
Switzerland. ConClusions: Integrating AMNOG discount in the list price impacts 
significantly the price in European countries due to ERP.
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objeCtives: To investigate the adequacy of the widely used Cobb-Douglas 
and translog models of the production functions of hospital in-patient ser-
vices. Methods: To investigate the adequacy of the widely used Cobb-Douglas 
and translog models of the production functions of hospital in-patient services, 
we fitted these and additive models (AMs) to 2002-2007 data for the gynaecology 
and obstetrics, general and digestive surgery, internal medicine, and traumatol-
ogy and orthopaedic surgery services of 10 public hospitals in Galicia (NW Spain). 
Production, measured as admissions weighted in accordance with their diagnosis-
related groups (DRGs), was treated as a function of physician full-time equivalents 
as surrogate labour factor and number of beds as surrogate capital factor. Results: 
For the General Surgery specialty the findings for the CD model indicate a better 
fit than those for the Translog and the AM, as it is shown by AIC value while R2 
(CD= 96.32, Translog= 96.30, AM= 98.30) prefers the flexible AM. This is a good exam-
ple of using AM as a tool for checking the behaviour of existing parametric models. 
In this case we can be confident with Cobb-Douglas estimations. Findings for the 
Internal Medicine specialty indicate responses for the CD (AIC= -17.789) seems to be 
more “robust” than those based on the AM (AIC= -13.113) and Translog (AIC= -15.939) 
models, R2 (CD= 95.88, Translog= 95.80, AM= 97.90) shows better fit for the AM regres-
sion model. ConClusions: Our results suggest that while the Cobb-Douglas and 
translog models suffice to represent the production functions of services with low 
average DRG weight, the greater flexibility of models such as AMs is required for 
services with higher average DRG weight.
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objeCtives: Sex differences in drug use have been demonstrated in several thera-
peutic area. However, there is a lack of overviews on sex differences of drug use in 
entire populations. The aim of this study was to describe difference in prevalence 
of drugs use in the entire population in Italy between men and women. Methods: 
We performed a cross-sectional study using 2012 data from the IMS LifeLink 
Treatment DynamicsTM LRx Database, an italian-based administrative database 
that includes all prescribed drugs that are reimbursed by the Italian National 
Healthcare System. Pharmacological groups accounting for > 90% of the total 
volume in Defined Daily Doses were considered. Crude and age adjusted differ-
ences in prevalence were calculated as risk ratios of women/men. Results: 31 
therapeutic categories were analyzed and there are significant differences for 30 
of them. The largest sex difference in prevalence was found for thyroid prepara-
tions that were more common in women (59.3/1000 women and 10.9/1000 men, 
respectively). This was followed by antiinflammatory and antirheumatic products 
(114.0/1000 women and 67.4/1000 men) and antidepressants (62.1/1000 women 
and 26.8/1000 men). The pharmacological groups with the largest relative differ-
ences of dispensed drugs were drugs affecting bone structure and mineralization 
(RR 12.4), calcium (RR 7.0) and thyroid therapy (RR 4.9), which were dispensed to 
women to a higher degree. Antigout-agents (RR 0.4), vasodilators used in cardiac 
diseases (RR 0.7) and ACE inhibitors (RR 0.7) were dispensed to men to a larger 
proportion. ConClusions: This is the first Italian study that shows substantial 
differences between men and women. Our findings are congruent with those 
reported previously in the literature. Some of differences may be explained by 
variations in disease prevalence and severity, pathophysiology, or by other biologi-
cal differences. However, it is also evident that other differences lack a rational 
medical explanation.
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objeCtives: The Human Capital Theory emphasizes investments to the health 
care sector as an important element in achieving and sustaining economic devel-
opment. Investments to health care sector improves macro and micro economic 
outcomes for the whole society. The aim of this study is to calculate the possible 
produced value for a life-time term (VLT) and cost of pre-mature deaths (CPD) 
from the productivity for USA, Canada, Japan and Australia. Methods: Net pre-
sent value (NPV) of the taxes and spending for each year were calculated. For 
calculating NPV in the government perspectives, two modelling approaches were 
combined, human capital modelling based on lives saved and lost productivity, 
and generational accounting, which accounts for a range of other government 
fiscal transfers to citizens. The possible produced value for a life-time term for 
each country were assumed as calculating the total NPV for each country depend-
ing on the countries life expectancy. CPD for each countries were assumed as the 
difference between NPV on the year of life expectancy and each decades as life 
years 60, 50, 40, 30, 20, 10. The economic values for the model of each country 
derived from World Bank, OECD, UNESCO or WHO. Results: Possible produced 
value for a life-time term for each country were calculated as US $ 1.415.530, US$ 
774.663, US$ 238.236 and US$ 2.917.835 for USA, Canada, Japan and Australia, 
respectively. CPD per person for USA were calculated as US$ -1.526.126, US$ 
-1.661.257, US$ -1.300.923, US$ -796.547, US$ - 351.827 and US$ -40.507 for the life 
years 10, 20, 30, 40, 50 and 60 respectively. The trend was same for Canada, Japan 
and Australia. ConClusions: However the study was based on a hypothetical 
model that calculated the NPV with the taxes and spending in a life-time term, 
the results of each country were parallel.
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objeCtives: Based on the content of drugs in households, it is possible to examine 
the inclination of patients towards self-medication and groups of drugs that are 
commonly used for this purpose. Taking into consideration the above, the present 
study aimed to investigate the self-medication practice, with an emphasis on 
self-medication with prescription only medications. Methods: The study was 
performed in 8 months period and involved 383 randomly selected households. 
The study consisted of a personal insight into the inventory of all drugs. The inter-
viewer recorded the total number of drugs in households and asked respondents 
for each the drug was obtained on prescription or bought in the pharmacy for 
self-medication. After the data were collected, drugs were classified according the 
Anatomical Therapeutic Chemical (ATC) Classification System. Drugs were also 
classified according to ALIMS (Medicines and Medical Devices Agency of Serbia) 
into two groups: prescription only medication (POM) and OTC (Over the Counter) 
drugs and then analyzed. Results: The total number of drug items present in 
the 383 households was 4384 with an average of 11.4±5.8 per household. More 
than a half of drugs in households were prescription only medications (58,5%). 
Approximately one third of these drugs were obtained without prescription. The 
most common prescription only medications obtained without prescription 
were anti-inflammatory and antirheumatic products (41,8%) and antibacterials 
for systemic use (12,4%). Ibuprofen (61,0%), diclofenac (27,8%) and nimesulide 
(8,2%) were the most common self-medicated drugs in the group of antiinflama-
tory drugs, while the most frequently self-medicated antibiotics were cefalexin 
(25,7%), doxyciclin (18,6%), cotrimoxazole (17,7%). ConClusions: In conclusion, 
our survey indicated that self-mediation with prescription drugs appeared to be 
a rather common practice, which is far away from the concept of “responsible 
self-medication”, especially regarding antibiotics. ACKnoWledGeMent: This 
work was supported by the Ministry of Science and Technological development, 
Republic of Serbia, project No. 41012.
